Molecular Mechanism and Targeted Therapy Strategy of Breast Cancer Metastasis and Drug Resistance
Contents
Chair(s)
Prof. Hailin Tang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
Recognized in the Annual Science Impact Ranking of the world's top 2% scientists in both 2023 and 2024, he has been dedicated to investigating the molecular mechanisms underlying malignant tumor pathogenesis and metastasis.
Prof. Qifeng Yang
Qilu Hospital, Shandong University, Jinan, Shandong, China.
Chairman of Department of Breast Cancer Surgery in Qilu Hospital, and Director of Research Institute for Breast Cancer Research of Shandong University. He is the winner of the National High-Level Talent Award and special foundation for Taishan Scholars, awardee of the first batch of Outstanding Young Talents of Qilu Hospital, recipient of the “Good mentor in my mind” Award of Shandong University and the Astra Zeneca Scholars Award.
Speaker(s)
Dr. Jindong Xie
Institute: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Dr. Xudong Zhu
Affiliated Oncology Hospital of Dalian University of Technology；Liaoning Key Laboratory of Precision Medicine for Malignant Tumors，Liaoning, China; University of Kentucky, USA.
Dr. Yutian Zou
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Dr. Hongling Liang
Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou, Guangdong, China.
Dr. Ning Zhang
Qilu Hospital, Shandong University, Jinan, Shandong, China.
Programme
Programme
| Time(UTC+8) | Speaker | Topics |
| 5:00-5:05(PM) | Prof. Qifeng Yang | Welcome Remarks |
| 5:05-5:10(PM) | Prof. Hailin Tang | Welcome Remarks |
| 5:10-5:20(PM) | Dr. Ning Zhang | The mechanism of carcinogenic metabolite-mediated M⁶ A epigenetic modification in triple-negative breast cancer metastasis |
| 5:20-5:30(PM) | Dr. Yutian Zou | Molecular mechanism and targeting strategy of anti-HER2 therapy resistance in breast cancer |
| 5:30-5:40(PM) | Dr. Jindong Xie | Methylation of GPRCSA promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer |
| 5:40-5:50(PM) | Dr. Xudong Zhu | Targeting KK-LC-1 inhibits the malignant biological behaviors of triple-negative breast cancer |
| 5:50-6:00(PM) | Dr. Hongling Liang | Mechanisms of drug resistance and treatment strategies for HER2-positive breast cancer |
| 6:00-6:20(PM) | All | Discussion |
| 6:20-6:25(PM) | Prof. Qifeng Yang Prof. Hailin Tang | Closing Remarks |
